BioSpace News Archive

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line results from Cohort 2 of its ongoing Phase 2/3 randomized, double-blind, placebo-controlled clinical study (iNO-PF) of INOpulse® for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD).

Thrive to analyze more than five years of Blue Cross and Blue Shield claims to detect cancer earlier and more cost-effectively

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that the Company is nearing completion of the second production cycle, of recombinant spider silk, at its Vietnamese production factory.

Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, and Ro, a leading U.S. telehealth provider, announced today they will partner to offer high-quality remote care dedicated to weight management and prescription fulfillment of Plenity

Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced the initiation of a phase 2 clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290.

Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new cohesive ophthalmic viscosurgical device intended to provide cataract surgeons with a new option in the continuum of cohesive and dispersive viscoelastics, which are used to create and maintain space in the anterior segment of the eye during cataract surgery.

The new operating unit will offer products and services formerly supplied separately by its Colorite, Natvar and Dunn businesses.

Florida Panhandle is the company’s sixth acquisition in the state of Florida and provides anesthesia services to a single GI ambulatory surgery center.

The value delivered is significant as it improves efficiencies.

Optimega Creates Drinkable Omega-3 Shots With A Higher Bioavailability Than Traditional Capsules